Concept Therapeutics (CORT), 'Relacorilant' approved by the FDA… ovarian cancer survival extended by 4.1 months to 16 months

Concept Treatment Company (CORT) has recently continued to release clinical achievements in the cardiovascular and anti-cancer fields, along with news that it has received approval from the U.S. Food and Drug Administration (FDA). Centered on its core drug “Rylacocorianth,” it is rolling out a comprehensive growth narrative. In particular, having confirmed meaningful data in the treatment of refractory hypertension and ovarian cancer, market attention toward CORT’s long-term corporate value is increasing.

On the 28th local time, CORT announced the results of its “MOMENTUM” clinical trial at the American College of Cardiology (ACC) 2026 Annual Meeting in the United States, stating that among 1,086 patients with resistant hypertension, 27.3% were confirmed to have “endogenous cortisol overproduction.” This proportion is consistent with the earlier “CATALYST” study results. Especially among high-risk groups with higher glycated hemoglobin (HbA1c) and those taking multiple antihypertensive drugs, the proportion rose to 36.6%. This suggests that cortisol regulation may become a key variable in the management of cardiovascular diseases.

In the anti-cancer area, the achievements of “Rylacocorianth” are even more striking. On March 25, CORT obtained FDA approval for a combination therapy of Rylacocorianth with the anti-cancer drug “Nab-Paclitaxel” as a platinum-resistant ovarian cancer treatment. In the Phase 3 “ROSELLA” clinical trial involving 381 patients, the overall survival (OS) reached 16.0 months—an increase of 4.1 months versus existing therapies (HR 0.65)—and it also demonstrated that the risk of disease progression was reduced by 30% (HR 0.70). Rylacocorianth was the first case approved by the FDA as a “selective glucocorticoid receptor antagonist.”

However, on the safety front, adverse effects such as neutropenia, infections, adrenal insufficiency, and fetal toxicity have been confirmed, which could affect future prescribing guideline updates and the pace of market promotion. Even so, industry assessments believe that, among patient populations with limited existing treatment options, it has demonstrated an improvement in survival rates, carrying substantial clinical significance.

In financial terms, the company’s performance has also remained steady. In 2025, CORT achieved annual sales of $761.4 million (approximately KRW 1.0958 trillion), net profit of $99.7 million (approximately KRW 143.6 billion), and set a revenue guidance for 2026 of $900 million to $1.0 billion (approximately KRW 1.296 trillion to KRW 1.44 trillion). As of year-end, cash and investment assets totaled $532.4 million (approximately KRW 766.3 billion), providing funding to conduct additional clinical trials and expand product pipeline reserves.

On the other hand, CORT encountered a somewhat unfavorable outcome in its patent dispute with Teva Pharmaceutical. The U.S. Court of Appeals for the Federal Circuit ruled that Teva’s generic drug “Corialim” sales did not infringe CORT’s patent, and upheld the original decision. In response, the company said it was “disappointing” and is considering further legal responses.

Industry views hold that CORT’s future value depends on the expansion of indications for “Rylacocorianth” and subsequent clinical trial results. At present, a Phase 3 clinical trial targeting amyotrophic lateral sclerosis (ALS) is also being prepared, and the European Medicines Agency’s (EMA) review is progressing in parallel. “Commenting” a global pharmaceutical analyst said: “CORT has built a unique platform connecting rare diseases and anti-cancer treatments,” and “Rylacocorianth has every potential to grow into a blockbuster drug.”